SCHEMBL183542

SCHEMBL183542

Oc1cc[c]cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717094 0.79
SCHEMBL57893 0.75
SCHEMBL127281 0.75
SCHEMBL27563466 0.72
SCHEMBL28968854 0.72
SCHEMBL2886283 0.72
SCHEMBL161731 0.70
SCHEMBL16719824 0.69 ESR2 (0.43)
SCHEMBL27688204 0.69 PIK3CA (0.38)
SCHEMBL717093 0.69 HSD17B1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399206-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES Redona Therapeutics, Inc. (US) 2024-07-17 EP claimed
CN-118201914-A 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors 雷多纳治疗公司 2024-06-14 CN claimed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 US claimed
WO-2023225359-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO claimed
US-20230084927-A1 GLUCOSE UPTAKE INHIBITORS AND USES THEREOF METABOMED LTD. (IL) 2023-03-16 US claimed
WO-2023039089-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES TWENTYEIGHT-SEVEN, INC. (US) 2023-03-16 WO claimed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 CN claimed
EP-3997083-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE Idorsia Pharmaceuticals Ltd (CH) 2022-05-18 EP claimed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US claimed
CN-114127066-A Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase 爱杜西亚药品有限公司 2022-03-01 CN claimed
EP-0761673-A1 Cephalosporin derivatives F. HOFFMANN-LA ROCHE AG (CH) 1997-03-12 EP claimed
US-5594011-A Modulators of acetylcholine receptors SIBIA NEUROSCIENCES, INC. (US) 1997-01-14 US claimed
EP-0739342-A1 PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS SIBIA NEUROSCIENCES, INC. (US) 1996-10-30 EP claimed
WO-1996015123-A1 PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS SIBIA NEUROSCIENCES, INC. (US) 1996-05-23 WO claimed
EP-0295341-A1 Cephalosporins Pfizer Corporation (PA) 1988-12-21 EP claimed
US-4236001-A 7β-Acyloxy-3-heterocyclicthiomethyl cephalosporins SMITHKLINE CORPORATION (US) 1980-11-25 US claimed
US-4220644-A BACTERICIDES SMITHKLINE CORPORATION (US) 1980-09-02 US claimed
US-4103086-A 8-Oxo-4-thia-1-azabicyclo (4.2.0)-oct-2-ene derivatives SMITHKLINE CORPORATION (US) 1978-07-25 US claimed
US-4048311-A ANTIBACTERIAL SMITHKLINE CORPORATION (US) 1977-09-13 US claimed
US-4020057-A 7β-Acyloxy cephalosporins SMITHKLINE CORPORATION (US) 1977-04-26 US claimed